SynthesisAllergy2026
Microbiota Signatures in Early Life and Their Association With Food Allergy: A Systematic Review.
Synthesis in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Food allergy (FA) is increasing worldwide, and early life may be a critical window for immune training. We systematically reviewed observational human studies linking early-life microbiota (infant, maternal, environmental, or extraintestinal) profiled using culture-based and/or culture-independent methods (including sequencing-based approaches) to subsequent FA or food sensitization outcomes in infants, children, and adolescents up to 18 years of age. PubMed, Web of Science Core Collection, Embase, Scopus, and LILACS were searched from database inception to March 2026. Inclusion required microbiota sampling during pregnancy or childhood and clinically ascertained FA/sensitization; non-human studies and studies without sequencing or clinical outcomes were excluded. Risk of bias was assessed using QUIPS. Owing to heterogeneity, we performed narrative synthesis. Forty studies were included (n = 6530 participants; 2077 cases). Across cohorts, cases were associated with lower diversity, early beta-divergence (1-6 months), neonatal enrichment of Proteobacteria (Pseudomonadota)/Enterobacteriaceae and selected taxa (Clostridium, Streptococcus, Sutterella), and depletion within the first year of Bifidobacterium, Blautia, and butyrate producers (Roseburia, Faecalibacterium). Functional profiles often suggested delayed maturation and reduced short-chain fatty acid capacity. Evidence was limited by moderate risk of bias, residual confounding, and heterogeneous outcome definitions. These findings support distinct early-life microbial configurations associated with FA susceptibility versus tolerance, informing mechanism-based prevention. Trial Registration: PROSPERO CRD420251234739.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.